MA47508A - Protéines de liaison à cd33, nkg2d et cd16 - Google Patents

Protéines de liaison à cd33, nkg2d et cd16

Info

Publication number: MA47508A
Authority: MA; Morocco
Prior art keywords: nkg2d; binding proteins; proteins; binding
Prior art date: 2017-02-20

Application number

MA047508A

Other languages

English (en)

Inventor

Gregory P Chang

Ann F Cheung

William Haney

Bradley M Lunde

Bianka Prinz

Original Assignee

Dragonfly Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-20

Filing date

2018-02-20

Publication date

2021-03-17

2018-02-20 Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc

2021-03-17 Publication of MA47508A publication Critical patent/MA47508A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Display Devices Of Pinball Game Machines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA047508A 2017-02-20 2018-02-20 Protéines de liaison à cd33, nkg2d et cd16 MA47508A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762461145P	2017-02-20	2017-02-20

Publications (1)

Publication Number	Publication Date
MA47508A true MA47508A (fr)	2021-03-17

Family

ID=63169992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047508A MA47508A (fr)	2017-02-20	2018-02-20	Protéines de liaison à cd33, nkg2d et cd16

Country Status (12)

Country	Link
US (1)	US20210130471A1 (fr)
EP (1)	EP3583131A4 (fr)
JP (3)	JP2020510646A (fr)
KR (1)	KR20190120775A (fr)
CN (1)	CN110573530A (fr)
AU (1)	AU2018220734B2 (fr)
BR (1)	BR112019017277A2 (fr)
CA (1)	CA3054078A1 (fr)
IL (1)	IL268790A (fr)
MA (1)	MA47508A (fr)
SG (1)	SG11201907638QA (fr)
WO (1)	WO2018152516A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110944651A (zh)	2017-02-08	2020-03-31	蜻蜓疗法股份有限公司	用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (fr)	2017-02-20	2024-01-17	Dragonfly Therapeutics, Inc.	Protéines se liant à her2, nkg2d et cd16
CA3090244A1 (fr)	2018-02-08	2019-08-15	Dragonfly Therapeutics, Inc.	Domaines variables d'anticorps ciblant le recepteur nkg2d
MX2020008333A (es)	2018-02-08	2020-09-21	Dragonfly Therapeutics Inc	Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh)	2018-02-20	2020-12-22	蜻蜓治疗公司	结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EA202091977A1 (ru) *	2018-05-28	2021-02-09	Драгонфлай Терапьютикс, Инк.	Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
CN113164570B (zh)	2018-08-08	2024-05-14	蜻蜓疗法股份有限公司	结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (fr)	2018-08-08	2020-02-13	Dragonfly Therapeutics, Inc.	Proteines de liaison multi-specifiques se liant a bcma, nkg2d et cd16, et methodes d'utilisation
SG11202103832SA (en) *	2018-11-07	2021-05-28	Crispr Therapeutics Ag	Anti-cd33 immune cell cancer therapy
CN113121697B (zh) *	2019-12-31	2023-06-09	周易	Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用
AU2021268340A1 (en)	2020-05-06	2022-12-08	Dragonfly Therapeutics, Inc.	Proteins binding NKG2D, CD16 and CLEC12A
EP4175656A4 (fr) *	2020-07-03	2024-10-16	The Trustees of Columbia University in the City of New York	Chimères de protéine orthogonale polyfonctionnelle
EP4301774A4 (fr)	2021-03-03	2025-08-13	Dragonfly Therapeutics Inc	Méthodes de traitement du cancer à l'aide de protéines de liaison multi-spécifiques qui se lient à nkg2d, à cd16 et à un antigène associé à une tumeur
CN115197330B (zh) *	2021-04-14	2023-04-28	广州百暨基因科技有限公司	同时靶向cll1和cd33的嵌合抗原受体及其应用
CN116948029A (zh) *	2022-04-20	2023-10-27	南京融捷康生物科技有限公司	一种包含IgG类Fc区变体的抗体及其用途
WO2024040195A1 (fr)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditionnement pour l'ingénierie de cellules immunitaires in vivo
EP4719352A1 (fr)	2023-05-31	2026-04-08	Capstan Therapeutics, Inc.	Formulations et compositions de nanoparticules lipidiques
US20250127728A1 (en)	2023-10-05	2025-04-24	Capstan Therapeutics, Inc.	Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (fr)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
US20250302763A1 (en)	2024-02-22	2025-10-02	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217452A1 (fr)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025217454A2 (fr)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Lipides cationiques ionisables et nanoparticules lipidiques
WO2025245271A1 (fr) *	2024-05-21	2025-11-27	Dragonfly Therapeutics, Inc.	Anticorps anti-nkg2d et leurs procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1266014A2 (fr) *	2000-03-24	2002-12-18	Peter Kufer	Polypeptides multifonctionnnels comportant un site de fixation d'un du complexe recepteur nkg2d
CL2007002668A1 (es) *	2006-09-20	2008-05-09	Amgen Inc	Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
WO2009077483A1 (fr) *	2007-12-14	2009-06-25	Novo Nordisk A/S	Anticorps humains anti-nkg2d et leurs utilisations
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (de) *	2009-09-25	2011-04-14	Technische Universität Dresden	Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
EP2332994A1 (fr) *	2009-12-09	2011-06-15	Friedrich-Alexander-Universität Erlangen-Nürnberg	Thérapie trispécifique contre la leucémie myéloïde aiguë
EP3587448B1 (fr) *	2013-03-15	2021-05-19	Xencor, Inc.	Protéines hétérodimériques
WO2014198748A1 (fr) *	2013-06-11	2014-12-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps à domaine unique anti-her2, polypeptides comportant de tels anticorps et leur utilisation pour le traitement du cancer
EP4050026A1 (fr) *	2014-04-01	2022-08-31	Adimab, LLC	Procédé d'obtention ou d'identification d'une ou plusieurs chaînes légères communes à utiliser dans la préparation d'un anticorps multispécifique
US10647768B2 (en) *	2014-05-29	2020-05-12	Macrogenics, Inc.	Multi-chain polypeptide-containing tri-specific binding molecules
EP2985294A1 (fr) *	2014-08-14	2016-02-17	Deutsches Krebsforschungszentrum	Molécule d'anticorps de recombinaison et son utilisation pour l'activation des lymphocytes T restreints de cellule cible
EP3180359A1 (fr) *	2014-08-14	2017-06-21	Novartis AG	Traitement du cancer à l'aide du récepteur d'antigène chimérique gfr alpha-4
ES2688035T3 (es) *	2014-08-29	2018-10-30	Gemoab Monoclonals Gmbh	Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
ES2717308T3 (es) *	2014-12-06	2019-06-20	Gemoab Monoclonals Gmbh	Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
CN107530424A (zh) *	2015-02-20	2018-01-02	俄亥俄州国家创新基金会	针对nkg2d和肿瘤相关抗原的二价抗体
ES2958720T3 (es) *	2015-06-10	2024-02-13	Immunitybio Inc	Células NK-92 modificadas para tratar el cáncer
JP6840682B2 (ja) *	2015-06-23	2021-03-10	イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅＰｈａｒｍａＰｈａｒｍａＳ．Ａ．	多重特異的抗原結合タンパク質
US11291721B2 (en) *	2016-03-21	2022-04-05	Marengo Therapeutics, Inc.	Multispecific and multifunctional molecules and uses thereof
CN110944651A (zh) *	2017-02-08	2020-03-31	蜻蜓疗法股份有限公司	用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途

2018
- 2018-02-20 AU AU2018220734A patent/AU2018220734B2/en not_active Expired - Fee Related
- 2018-02-20 KR KR1020197026921A patent/KR20190120775A/ko not_active Ceased
- 2018-02-20 US US16/486,921 patent/US20210130471A1/en not_active Abandoned
- 2018-02-20 SG SG11201907638QA patent/SG11201907638QA/en unknown
- 2018-02-20 BR BR112019017277-7A patent/BR112019017277A2/pt not_active IP Right Cessation
- 2018-02-20 CN CN201880026148.9A patent/CN110573530A/zh active Pending
- 2018-02-20 JP JP2019545316A patent/JP2020510646A/ja active Pending
- 2018-02-20 EP EP18753685.9A patent/EP3583131A4/fr active Pending
- 2018-02-20 WO PCT/US2018/018768 patent/WO2018152516A1/fr not_active Ceased
- 2018-02-20 CA CA3054078A patent/CA3054078A1/fr active Pending
- 2018-02-20 MA MA047508A patent/MA47508A/fr unknown
2019
- 2019-08-19 IL IL26879019A patent/IL268790A/en unknown
2023
- 2023-01-05 JP JP2023000416A patent/JP2023052214A/ja active Pending
2025
- 2025-01-07 JP JP2025002125A patent/JP2025061059A/ja active Pending

Also Published As

Publication number	Publication date
IL268790A (en)	2019-10-31
JP2025061059A (ja)	2025-04-10
KR20190120775A (ko)	2019-10-24
EP3583131A1 (fr)	2019-12-25
WO2018152516A1 (fr)	2018-08-23
RU2019129174A3 (fr)	2021-07-02
RU2019129174A (ru)	2021-03-22
CN110573530A (zh)	2019-12-13
US20210130471A1 (en)	2021-05-06
SG11201907638QA (en)	2019-09-27
AU2018220734A1 (en)	2019-09-12
AU2018220734B2 (en)	2025-03-06
CA3054078A1 (fr)	2018-08-23
BR112019017277A2 (pt)	2020-04-14
JP2020510646A (ja)	2020-04-09
EP3583131A4 (fr)	2021-03-17
JP2023052214A (ja)	2023-04-11

Publication	Publication Date	Title
IL268567A (en)	2019-09-26	Proteins binding bcma, nkg2d and cd16
MA50255A (fr)	2021-05-26	Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
IL268790A (en)	2019-10-31	CD33, NKG2D and CD16 binding proteins
IL268755A (en)	2019-10-31	Proteins binding her2, nkg2d and cd16
IL281305A (en)	2021-04-29	Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
IL272374A (en)	2020-03-31	Proteins binding nkg2d, cd16 and flt3
EP3655432A4 (fr)	2021-04-14	Protéines de liaison 1
EP3679071A4 (fr)	2021-06-09	Protéines de liaison à nkg2d, cd16 et un antigène associé à une tumeur
IL270794A (en)	2020-01-30	NKG2D binding protein, CD16 and ROR1 or ROR2
EP3802581A4 (fr)	2022-04-13	Protéines de liaison multispécifiques et améliorations de celles-ci
IL280512A (en)	2021-03-25	Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3641762A4 (fr)	2021-03-10	Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
IL270803A (en)	2020-01-30	A protein binding nkg2d, cd16 and a tumor-associated antigen
EP3680331A4 (fr)	2021-06-09	Protéine cas9 modifiée et utilisation de celle-ci
IL268574A (en)	2019-09-26	proteins that bind psma, nkg2d, and cd16
EP3633034A4 (fr)	2021-03-24	PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP3630181A4 (fr)	2021-03-17	Protéine de liaison nkg2d, cd16 et antigène associé à une tumeur
IL268768A (en)	2019-10-31	Proteins binding gd2, nkg2d and cd16
IL268766A (en)	2019-10-31	Proteins that bind NKG2D, CD123, and CD16
DK3275895T3 (da)	2021-09-27	Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
IL286929A (en)	2021-10-31	Trispecific binding proteins, methods, and uses thereof
EP3833385A4 (fr)	2021-12-22	Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EP3689893A4 (fr)	2021-12-15	Protéine de liaison à l'immunoglobuline, et support d'affinité mettant en uvre celle-ci
EP3445394A4 (fr)	2020-02-19	Protéines de liaison à alk7 et leurs utilisations
EP3882277A4 (fr)	2022-08-03	Protéine de fusion et son utilisation